Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Viemed Healthcare Inc VMD

Viemed Healthcare, Inc. through its subsidiaries, is a provider of home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counselling to patients in their homes using cutting edge technologies. The Company’s products and services include Home Medical Equipment, In-home sleep testing, and Healthcare staffing. Home Medical Equipment provides respiratory and other home medical equipment, including home ventilation, bi-level positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP) devices, percussion vests, and other medical equipment. In-home sleep testing provides in home sleep apnea testing services. Healthcare staffing provides healthcare staffing and recruitment services. The Company provides home medical equipment services through its interest in East Alabama HomeMed, LLC (HomeMed).


NDAQ:VMD - Post by User

Comment by stockfyon Jun 04, 2021 8:53am
133 Views
Post# 33328474

RE:VMD: Dirt-cheap at <2x revenue and <7x adj. EBITDA in 2021

RE:VMD: Dirt-cheap at <2x revenue and <7x adj. EBITDA in 2021All these facts below hurt besttobe alias and his agenda against VMD.
 
Besttobe alias, the resident disgruntled employee, created his alias in 2019 and he has posted numerous negative messages on VMD's board over the last couple of years.

In his numerous messages, besttobe alias has twisted the truth multiple times and/or he has made highly inaccurate remarks or he has posted outright lies. Pathetic.


stockfy wrote:

VMD has overreacted over the last days and has become technically oversold. Technicals aside, VMD's revenue and adj. EBITDA in 2021 will be at least $150 million and $45 million, respectively.

VMD also has a pristine balance sheet with net cash of about $24 million, I mean the cash exceed debt by $24 million.

As a result, VMD's Enterprise Value currently is less than 2 times its 2021 revenue and less than 7 times its 2021 adj. EBITDA, so VMD is dirt-cheap on relative and absolute valuation analysis! 

The aforementioned estimates do not include extra revenue coming from the many growth initiatives mentioned in the latest two Conference Calls, especially the last CC.

Both the CEO and the COO were very clear in the latest Conference Call.

VMD has been working on many fronts and will increase significantly its revenue this year thanks to organic and inorganic (acquisitions) initiatives.
 







<< Previous
Bullboard Posts
Next >>